Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial.
The Abstract appears here.
The study looked at data from the European Organisation for Research and Treatment of Cancer (EORTC) trial which randomized 670 women to receive surgery first or neoadjuvant chemotherapy. Neaoadjuvant treatment is a treatment given to shrink a tumor before treatment. The treatment could be chemotherapy, hormone therapy, radiation. In this study only chemotherapy was used as the neoadjuvant treament. The study also examined biomarkers to see if they could predict whether surgery or neoadjuvant chemotherapy was best. The study endpoint was overall survival.
Results: The study found women staged IIIC or less and smaller ( < 45 mm) metastatic tumors had higher survival rates with surgery first. Women at stage IV with large ( >45mm) metastatic tumors had better survival with neoadjuvant chemotherapy. For other patients the treatments were comparable.
Every Day is a Blessing!